Growth • Kura Oncology

KURA

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

21,1%

CAGR Op. Income 5Y

Operating Income Compound Annual Growth Rate in the last 5 years.

19,3%

CAGR Net Income 5Y

Net Income Compound Annual Growth Rate in the last 5 years.

8%

CAGR EPS 5Y

Earnings Per Share Compound Annual Growth Rate in the last 5 years.

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!

Unrestricted access
Unlimited data history
Analysis videos
Quarterly highlights
Customizable financials table
Ranking
Discussions

...and much more!